PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,079)

Items 501–600 of 1,079

1. Chemotherapy for hepatocellular carcinoma: current status and future perspectives
   Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takuji Okusaka, Hiroshi Ishii, Junji Furuse · 2017 · Japanese Journal of Clinical Oncology
2. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
   Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia et al. · 2021 · Cancer Discovery
3. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
   Kumar, Anil, Gautam, Vipasha, Sandhu, Arushi, Rawat, Kajal, Sharma, Antika, Saha, Lekha · 2023 · World Journal of Gastrointestinal Surgery
4. Immune system and melanoma biology: a balance between immunosurveillance and immune escape
   Anna Maria Passarelli, Francesco Mannavola, Luigia Stefania Stucci, Marco Tucci, Francesco Silvestris · 2017 · Oncotarget
5. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
   Michael Joe Duffy, John Paul Crown · 2019 · Clinical Chemistry
6. Cancer therapy with antibodies
   Suman Paul, Maximilian F. Konig, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M. Wright, Sandra B. Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou · 2024 · Nature reviews. Cancer
7. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
   Hui Zhou, Liyong Zhu, Jun Ho Song, Guohui Wang, Pengzhou Li, Weizheng Li, Ping Luo, Xulong Sun, Jin Wu, Yunze Liu et al. · 2022 · Molecular Cancer
8. Mechanisms of metastatic colorectal cancer
   Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle · 2024 · Nature Reviews Gastroenterology & Hepatology
9. LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
   Yayi He, Hui Yu, Leslie M. Rozeboom, Christopher J. Rivard, Kim E. Ellison, Rafał Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou et al. · 2017 · Journal of Thoracic Oncology
10. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    Pant, Shubham, Wainberg, Zev A., Weekes, Colin D., Furqan, Muhammad, Kasi, Pashtoon M., Devoe, Craig E., Leal, Alexis D., Chung, Vincent, Basturk, Olca, VanWyk, Haley et al. · 2024 · Nature Medicine
11. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
    Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju‐Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong‐Wan Kim, Doo Hyun Chung, Dae Seog Heo · 2016 · Clinical Cancer Research
12. The current state of molecular testing in the treatment of patients with solid tumors, 2019
    El‐Deiry, Wafik S., Goldberg, Richard M., Lenz, Heinz‐Josef, Shields, Anthony F., Gibney, Geoffrey T., Tan, Antoinette R., Brown, Jubilee, Eisenberg, Burton, Heath, Elisabeth I., Phuphanich, Surasak et al. · 2019 · CA: A Cancer Journal for Clinicians
13. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
    Yi Kan Wang, Ali Bashashati, Michael S. Anglesio, Dawn R. Cochrane, Diljot S. Grewal, Gavin Ha, Andrew McPherson, Hugo M. Horlings, Janine Senz, Leah Prentice et al. · 2017 · Nature Genetics
14. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
    Alexandra Thomas, Eric D. Routh, Ashok Pullikuth, Guangxu Jin, Jing Su, Jeff W. Chou, Katherine A. Hoadley, Cristin Gregor Print, Nicholas S. Knowlton, Michael A. Black et al. · 2018 · OncoImmunology
15. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
    Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John A. Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind M. Javle et al. · 2021 · Cancer Discovery
16. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
    David A. Fabrizio, Thomas J. George, Richard Francis Dunne, Garrett Michael Frampton, James X. Sun, Kyle A. Gowen, Mark Kennedy, Joel R. Greenbowe, Alexa Betzig Schrock, Aram F. Hezel et al. · 2018 · Journal of Gastrointestinal Oncology
17. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
    Marc Oliva, Anna Spreafico, Miren Taberna, Laia Alemany, Bryan A. Coburn, Ricard Mesı́a, Lillian L. Siu · 2018 · Annals of Oncology
18. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
    Daphne Liselotte Van Der Velden, Louisa Rose Hoes, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Erik D. van Werkhoven, Paul Roepman, Richard L. Schilsky, Wendy W.J. de Leng, Alwin D. R. Huitema, Bastiaan Nuijen et al. · 2019 · Nature
19. TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
    Jiefei Han, Jianchun Duan, Hua Bai, Yuqi Wang, Rui Wan, Xin Wang, Si Chen, Yanhua Tian, Di Wang, Kailun Fei et al. · 2019 · Cancer Immunology Research
20. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
    Chao Liu, Ruiqi Liu, Bojun Wang, Jie Lian, Yang Yao, Haoxiu Sun, Chunhui Zhang, Lin Fang, Xin Guan, Jiaqi Shi et al. · 2021 · Journal for ImmunoTherapy of Cancer
21. A Convergence-Based Framework for Cancer Drug Resistance
    Konieczkowski, David J., Johannessen, Cory M., Garraway, Levi A. · 2018 · Cancer Cell
22. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
    Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Gordon Beattie, Andrew Rowan, Désirée Schnidrig, R. Houston Thompson, Fiona Byrne, Stuart D. Horswell et al. · 2021 · Cancer Cell
23. Determinants of metastatic competency in colorectal cancer
    Daniele V. F. Tauriello, Alexandre Calon, Enza Lonardo, Eduard Batlle · 2017 · Molecular Oncology
24. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
    Claudio Luchini, Lodewijk A.A. Brosens, Laura DeLong Wood, Deyali Chatterjee, Jae Il Shin, Concetta Sciammarella, Giulia Fiadone, Giuseppe Malleo, Roberto Salvia, Valentyna Kryklyva et al. · 2020 · Gut
25. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial
    André, Thierry, Elez, Elena, Lenz, Heinz-Josef, Jensen, Lars Henrik, Touchefeu, Yann, Van Cutsem, Eric, Garcia-Carbonero, Rocio, Tougeron, David, Mendez, Guillermo Ariel, Schenker, Michael et al. · 2025 · The Lancet
26. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies
    Sveen, Anita, Bruun, Jarle, Eide, Peter W., Eilertsen, Ina A., Ramirez, Lorena, Murumägi, Astrid, Arjama, Mariliina, Danielsen, Stine A., Kryeziu, Kushtrim, Elez, Elena et al. · 2018 · Clinical Cancer Research
27. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells
    Cañellas-Socias, Adrià, Cortina, Carme, Hernando-Momblona, Xavier, Palomo-Ponce, Sergio, Mulholland, Eoghan J., Turon, Gemma, Mateo, Lidia, Conti, Sefora, Roman, Olga, Sevillano, Marta et al. · 2022 · Nature
28. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
    Duan, Xiaopin, Chan, Christina, Han, Wenbo, Guo, Nining, Weichselbaum, Ralph R., Lin, Wenbin · 2019 · Nature Communications
29. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
    Patrick Alexander Ott, Sarina Anne Piha-Paul, Pamela N. Münster, Michael Jon Pishvaian, Emilie M.J. van Brummelen, Roger B. Cohen, Carlos Gomez‐Roca, Samuel Ejadi, Mark N. Stein, Emily W. Chan et al. · 2017 · Annals of Oncology
30. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
    Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles Cameron Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère et al. · 2019 · Cell Research
31. Nonoperative Management of Mismatch Repair–Deficient Tumors
    Andrea Cercek, Michael Bonner Foote, Benoı̂t Rousseau, Jesse Joshua Smith, Jinru Shia, Jenna Cohen Sinopoli, Jill A. Weiss, Melissa Amy Lumish, Lindsay Temple, Mitesh Patel et al. · 2025 · New England Journal of Medicine
32. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
    Sacher, Adrian G., Gandhi, Leena · 2016 · JAMA Oncology
33. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
    Marius Ilié, Véronique Hofman, Manfred Dietel, Jean‐Charles Soria, Paul M Hofman · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
34. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
    Bernard J. Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey Alan Sosman, Giuseppe Procopio, Elizabeth R. Plimack et al. · 2017 · European Urology
35. Racial Disparity in Gastrointestinal Cancer Risk
    Hassan Ashktorab, Sonia S. Kupfer, Hassan Brim, John M. Carethers · 2017 · Gastroenterology
36. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
    Rehan Ahmad, Jaikee Kumar Singh, Amoolya Wunnava, Omar Abdullah Al-Obeed, Maha‐Hamadien Abdulla, Sandeep Kumar Srivastava · 2021 · International Journal of Molecular Medicine
37. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
    Neda Stjepanovic, Leticia Moreira, Fátima Carneiro, Francesc Balaguer, Andrès M.R. Cervantes, Judith Balmañà, Erika Martinelli · 2019 · Annals of Oncology
38. The role of interleukin-17 in tumor development and progression
    Junjie Zhao, Xing Chen, Tomasz Herjan, Xiaoxia Li · 2019 · The Journal of Experimental Medicine
39. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
    Elisa González-Rodríguez, Delvys Rodríguez‐Abreu, on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) · 2016 · The Oncologist
40. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
    Hyung‐Don Kim, Gi‐Won Song, Seongyeol Park, Min Hwan Kim, Min Hwan Kim, Hyo Jeong Kang, Changhoon Yoo, Kyung Hwan Kim, Kyung Hwan Kim, Su-Kyeong Eo et al. · 2018 · Gastroenterology
41. Pharmacogenomics: Driving Personalized Medicine
    Wolfgang Sadée, Daqing Wang, Katherine Hartmann, Amanda Ewart Toland · 2023 · Pharmacological Reviews
42. Translational advances in pancreatic ductal adenocarcinoma therapy
    Abdel Nasser Hosein, Stephanie K. Dougan, Andrew J. Aguirre, Anirban Maitra · 2022 · Nature Cancer
43. Therapeutic targeting of regulatory T cells in cancer
    Feng Shan, Ashwin Somasundaram, Tullia Carmela Bruno, Creg J. Workman, Dario A.A. Vignali · 2022 · Trends in cancer
44. Prevalence ofPDL1Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
    Aaron Michael Goodman, David Eric Piccioni, Shumei Kato, Amélie Boichard, Huan‐You Wang, Garrett Michael Frampton, Scott Michael Lippman, Caitlin F. Connelly, David A. Fabrizio, Vincent A. Miller et al. · 2018 · JAMA Oncology
45. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
    Romain Cohen, Élisabeth Hain, Olivier Buhard, Agathe Guilloux, Armelle Bardier–Dupas, Rachid Kaci, Philippe Bertheau, Florence Renaud, Frédéric Bibeau, Jean–François Fléjou et al. · 2018 · JAMA Oncology
46. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
    Emma Jayne Crosbie, Neil A. J. Ryan, Mark Johan Arends, Tjalling Bosse, John Burn, Joanna M. Cornes, Robin Crawford, Diana Eccles, Ian M. Frayling, Sadaf Ghaem-Maghami et al. · 2019 · Genetics in Medicine
47. Colorectal Tumor Microenvironment‐Activated Bio‐Decomposable and Metabolizable Cu2O@CaCO3 Nanocomposites for Synergistic Oncotherapy
    Mengyu Chang, Zhiyao Hou, Dayong Jin, Jiajia Zhou, Man Wang, Meifang Wang, Mengmeng Shu, Binbin Ding, Chunxia Li, Jun Lin · 2020 · Advanced Materials
48. Current and future immunotherapeutic approaches in pancreatic cancer treatment
    Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, Ali‐Akbar Delbandi · 2024 · Journal of Hematology & Oncology
49. Hot and cold tumors: Immunological features and the therapeutic strategies
    Lianjie Wang, Hui Geng, Yujie Liu, Lei Liu, Yanhua Chen, Fanchen Wu, Zhiyi Liu, Shiliang Ling, Yan Wang, Lihong Zhou · 2023 · MedComm
50. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
    Pishvaian, Michael J., Bender, Robert J., Halverson, David, Rahib, Lola, Hendifar, Andrew E., Mikhail, Sameh, Chung, Vincent, Picozzi, Vincent J., Sohal, Davendra, Blais, Edik M. et al. · 2018 · Clinical Cancer Research
51. VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
    Kim, Chang Gon, Jang, Mi, Kim, Youngun, Leem, Galam, Kim, Kyung Hwan, Lee, Hoyoung, Kim, Tae-Shin, Choi, Seong Jin, Kim, Hyung-Don, Han, Ji Won et al. · 2019 · Science Immunology
52. Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
    Takehito Shukuya, David Paul Carbone · 2016 · Journal of Thoracic Oncology
53. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
    Feifei Teng, Xiangjiao Meng, Li Kong, Jinming Yu · 2017 · Cancer Letters
54. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
    Chong-xian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li, Lei Zheng · 2020 · Journal of Hematology & Oncology
55. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
    Shixiang Wang, Mingming Jia, Zaoke He, Xuesong Liu · 2018 · Oncogene
56. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
    Arsen Osipov, May Tun Saung, Lei Zheng, Adrian Gerard Murphy · 2019 · Journal for ImmunoTherapy of Cancer
57. Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
    Andrea Cercek, Gustavo dos Santos Fernandes, Campbell S.D. Roxburgh, Karuna Ganesh, Shu Ng, Francisco Sánchez-Vega, Rona D. Yaeger, Neil Howard Segal, Diane L. Reidy‐Lagunes, Anna M. Varghese et al. · 2020 · Clinical Cancer Research
58. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
    Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin, Radwa Sharaf, Nora Sánchez, Ameet Guria, Max Minker, Gerald Li, Virginia A. Fisher, Ethan S. Sokol et al. · 2020 · Cancer Discovery
59. The Immune Microenvironment in Pancreatic Cancer
    Magdalena Huber, Corinna U. Brehm, Thomas Mathias Gress, Malte Buchholz, Bilal Alashkar Alhamwe, Elke Pogge von Strandmann, Emily P. Slater, Jörg Walter Bartsch, Christian Alexander Bauer, Matthias Lauth · 2020 · International Journal of Molecular Sciences
60. The Immune Biology of Microsatellite-Unstable Cancer
    Matthias Kloor, Magnus von Knebel Doeberitz · 2016 · Trends in cancer
61. S3-Leitlinie – Kolorektales Karzinom
    Wolff Schmiegel, Barbara Buchberger, Markus Follmann, Ullrich Graeven, Volker Heinemann, Thomas G. Langer, Monika Nothacker, Rainer Porschen, Claus Michael Rödel, Thomas Rösch et al. · 2017 · Zeitschrift für Gastroenterologie
62. Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
    Leo Kager, Gevorg Tamamyan, Stefan Bielack · 2016 · Future Oncology
63. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
    Florent Peyraud, Antoîne Italiano · 2020 · Cancers
64. Tumor-infiltrating dendritic cell states are conserved across solid human cancers
    Genevieve M. Gerhard, Ruben Bill, Marius Messemaker, Allon Moshe Klein, Mikaël J. Pittet · 2020 · The Journal of Experimental Medicine
65. Development of PARP and immune-checkpoint inhibitor combinations
    Stewart, Ross A, Pilié, Patrick G, Yap, Timothy A · 2018 · Cancer Research
66. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
    Willem Joost Lesterhuis, Anthony Bosco, Michael Millward, MICHAEL P. SMALL, Anna K. Nowak, Richard Lake · 2017 · Nature Reviews Drug Discovery
67. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival
    Ludmila Danilova, Won Jin Ho, Qingfeng Zhu, Teena Vithayathil, Ana De Jesus‐Acosta, Nilofer Saba Azad, Daniel A. Laheru, Elana Judith Fertig, Robert A. Anders, Elizabeth M. Jaffee et al. · 2019 · Cancer Immunology Research
68. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
    Jason A. Willis, Martina I. Lefterova, Alexander Artyomenko, Pashtoon Murtaza Kasi, Yoshiaki Nakamura, Kabir Mody, Daniel V.T. Catenacci, Marwan Fakih, Cátálin Bárbácioru, Jing Zhao et al. · 2019 · Clinical Cancer Research
69. An overview of precision oncology basket and umbrella trials for clinicians
    Jay Park, Grace G. Hsu, Ellie G. Siden, Kristian Thorlund, Edward J. Mills · 2020 · CA A Cancer Journal for Clinicians
70. Advances in immunotherapy for colorectal cancer: a review
    Gol Minoo Golshani, Yue Zhang · 2020 · Therapeutic Advances in Gastroenterology
71. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Rina Hui, Edward B. Garon, J.W. Goldman, Natasha B. Leighl, Matthew David Hellmann, Amita Patnaik, Leena Gandhi, Joseph P. Eder, Myung‐Ju Ahn, Leora Horn et al. · 2017 · Annals of Oncology
72. Hallmarks of response to immune checkpoint blockade
    Alexandria P. Cogdill, Miles Cameron Andrews, Jennifer Ann Wargo · 2017 · British Journal of Cancer
73. Immune checkpoints in the tumor microenvironment
    Salman M. Toor, Varun Sasidharan Nair, Julie V. Decock, Eyad Elkord · 2019 · Seminars in Cancer Biology
74. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway
    Junhong Guan, Changzheng Lu, Qihuang Jin, Huiming Lu, Xiang Chen, Lei Tian, Yanbin Zhang, Janice Ortega, Junqiu Zhang, Silvia Siteni et al. · 2020 · Cancer Cell
75. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer
    Minsuk Kwon, Minae An, Samuel Jacob Klempner, Hyuk Lee, Kyoung‐Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min et al. · 2021 · Cancer Discovery
76. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
    Wenwen Du, Min Yang, Abbey Turner, Chunling Xu, Robert Louis Ferris, Jian‐An Huang, Larry Kane, Binfeng Lu · 2017 · International Journal of Molecular Sciences
77. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
    Xin Hong, Whijae Roh, Ryan Joseph Sullivan, Keith H.K. Wong, Ben S. Wittner, Hongshan Guo, Taronish D. Dubash, Moshe Sade-Feldman, Benjamin Wesley, E. Philip Horwitz et al. · 2020 · Cancer Discovery
78. Progress and challenges of immunotherapy in triple-negative breast cancer
    Yinxing Zhu, Xuedan Zhu, Cuiju Tang, Xiaoxiang Guan, Wenwen Zhang · 2021 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
79. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
    Olga Rodak, Manuel David Peris‐Díaz, Mateusz Olbromski, Marzenna Podhorska‐Okołów, Piotr Dzięgiel · 2021 · Cancers
80. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    A. Krämer, Tilmann Bochtler, Chantal Pauli, G. Baciarello, Stefan Delorme, Kari Hemminki, Linda Mileshkin, Holger Moch, Karin A. Oien, Timothée Olivier et al. · 2022 · Annals of Oncology
81. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
    Majidpoor, Jamal, Mortezaee, Keywan · 2021 · Clinical Immunology
82. Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
    Zsofia Kinga Stadler, Francesca Battaglin, Sumit Middha, Jaclyn Frances Hechtman, Christina Tran, Andrea Cercek, Rona D. Yaeger, Neil Howard Segal, Anna M. Varghese, Diane L. Reidy‐Lagunes et al. · 2016 · Journal of Clinical Oncology
83. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
    Cheri A. Pasch, Peter F. Favreau, Alexander E. Yueh, Christopher P. Babiarz, Amani A. Gillette, Joe T. Sharick, Mohammad Rezaul Karim, Kwangok P. Nickel, Alyssa K. DeZeeuw, Carley M. Sprackling et al. · 2019 · Clinical Cancer Research
84. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
    Zhouhong Ge, Maikel Petrus Peppelenbosch, Dave Sprengers, Jaap Kwekkeboom · 2021 · Frontiers in Immunology
85. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
    Chunwan Lu, Priscilla S. Redd, Jeffrey R. Lee, Natasha M. Savage, Kebin Liu · 2016 · OncoImmunology
86. Preclinical and clinical development of neoantigen vaccines
    L. Li, Simon Peter Goedegebuure, William E. Gillanders · 2017 · Annals of Oncology
87. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
    Dongqiang Zeng, Jiani Wu, Hui Luo, Yong Li, Jian Xiao, Jianjun Peng, Zilan Ye, Rui Zhou, Yunfang Yu, Gaofeng Wang et al. · 2021 · Journal for ImmunoTherapy of Cancer
88. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer
    Yohei Masugi, Reiko Nishihara, Juhong Yang, Kosuke Mima, Annacarolina da Silva, Yan Xia Shi, Kentaro Inamura, Yin Cao, Mingyang Song, Jonathan Andrew Nowak et al. · 2016 · Gut
89. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
    Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lü, Kyaw Zin Thein, Benjamin Scott S Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang et al. · 2021 · Nature Communications
90. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
    Roman M. Chabanon, Marion Pedrero, Céline Lefèbvre, Aurélien Marabelle, Jean‐Charles Soria, Sophie C. Postel-Vinay · 2016 · Clinical Cancer Research
91. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
    Fangjun Chen, Zhengyun Zou, Juan Du, Shu Su, Jie Shao, Fanyan Meng, Ju Dong Yang, Qiuping Xu, Naiqing Ding, Yang Yang et al. · 2019 · Journal of Clinical Investigation
92. Novel technologies and emerging biomarkers for personalized cancer immunotherapy
    Jianda D. Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden Terry Maecker, David B. Page et al. · 2016 · Journal for ImmunoTherapy of Cancer
93. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
    Jessica S. Brown, Raghav Sundar, Juanita Suzanne Lopez · 2017 · British Journal of Cancer
94. Prostate carcinogenesis: inflammatory storms
    Johann Sebastian De Bono, Christina W. Guo, Bora Gürel, Angelo Michael De Marzo, Karen Sandell Sfanos, Ram Shankar Mani, Jesús Gil, Charles G. Drake, Andrea Alimonti · 2020 · Nature reviews. Cancer
95. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
    Mark Selby, John Engelhardt, Robert J. Johnston, Li-Sheng Lu, Minhua Han, Kent B. Thudium, Dapeng Yao, Michael M. Quigley, Jose Valle, Changyu Wang et al. · 2016 · PLoS ONE
96. Circulating tumor DNA: current challenges for clinical utility
    Donna K. Dang, Ben Ho Park · 2022 · Journal of Clinical Investigation
97. Designing nanomedicine for immuno-oncology
    Wen Jiang, Christina A. Von Roemeling, Yuanxin Chen, Yaqing Qie, Xiujie Liu, Jianzhu Chen, Betty Y.S. Kim · 2017 · Nature Biomedical Engineering
98. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
    Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus Otho Butler, Mary Lenora Disis, Jérôme Galon, Leif Håkansson, Brent Allen Hanks, Vaios Karanikas, Samir N. Khleif et al. · 2017 · Journal for ImmunoTherapy of Cancer
99. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
    Jinfang Zhang, Fabin Dang, Junming Ren, Wenyi Wei · 2018 · Trends in Biochemical Sciences
100. Targeting immune cells for cancer therapy
     Sin Yee Gun, Sharon Wei Ling Lee, Je Lin Sieow, Siew Cheng Wong · 2019 · Redox Biology